LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+49.51%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$811M
AUM Growth
+$811M
(+49%)
Cap. Flow
+$84.2M
Cap. Flow
% of AUM
10.39%
Top 10 Holdings %
Top 10 Hldgs %
63.24%
Holding
45
New
13
Increased
4
Reduced
11
Closed
7
Top Buys
| 1 |
ALLK
Allakos
ALLK
|
$36.3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$26.9M |
| 3 |
Ascendis Pharma
ASND
|
$25.8M |
| 4 |
Viridian Therapeutics
VRDN
|
$20.5M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$18.1M |
Top Sells
| 1 |
Ventyx Biosciences
VTYX
|
$31.9M |
| 2 |
Neurocrine Biosciences
NBIX
|
$29.2M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.9M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$14.9M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$13.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $88.8M | 10.92% | 1,300,000 -200,000 | -13% | -$13.7M |
|
2
Cytokinetics
CYTK
$4.23B
| $82.4M | 10.13% | 1,700,000 -50,000 | -3% | -$2.42M |
|
3
IDEAYA Biosciences
IDYA
$2.15B
| $61.7M | 7.58% | 4,135,000 +385,000 | +10% | +$5.74M |
|
|
4
Ventyx Biosciences
VTYX
$171M
| $48.8M | 6% | 1,397,680 -915,000 | -40% | -$31.9M |
|
5
Design Therapeutics
DSGN
$315M
| $46.8M | 5.75% | 2,797,501 | – | – |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$511M
| $46.5M | 5.72% | 2,000,000 +300,000 | +18% | +$6.98M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $38.7M | 4.76% | 350,000 -50,000 | -13% | -$5.53M |
|
|
ALLK
8
DELISTED
Allakos
ALLK
| $36.3M | 4.47% | +5,936,666 | New | +$36.3M |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $33.7M | 4.15% | 150,000 | – | – |
|
10
Arcutis Biotherapeutics
ARQT
$1.86B
| $29.1M | 3.58% | 1,525,000 +525,000 | +53% | +$10M |
|
11
Dyne Therapeutics
DYN
$1.92B
| $29M | 3.57% | 2,287,321 -612,679 | -21% | -$7.78M |
|
12
ALX Oncology
ALXO
$62.7M
| $28.4M | 3.5% | 2,971,352 -165,000 | -5% | -$1.58M |
|
|
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $26.9M | 3.31% | +1,500,000 | New | +$26.9M |
|
|
14
Ascendis Pharma
ASND
$11.8B
| $25.8M | 3.17% | +250,000 | New | +$25.8M |
|
|
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $22M | 2.71% | 1,085,251 +100,000 | +10% | +$2.03M |
|
|
16
Viridian Therapeutics
VRDN
$1.5B
| $20.5M | 2.52% | +1,000,000 | New | +$20.5M |
|
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $18.1M | 2.22% | +500,000 | New | +$18.1M |
|
18
Immunocore
IMCR
$1.62B
| $16.4M | 2.02% | +350,000 | New | +$16.4M |
|
19
Fulcrum Therapeutics
FULC
$351M
| $15.8M | 1.94% | 1,950,000 | – | – |
|
20
Akero Therapeutics
AKRO
$3.74B
| $13.6M | 1.67% | +400,000 | New | +$13.6M |
|
|
NGM
21
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $11.1M | 1.37% | +850,000 | New | +$11.1M |
|
22
Olema Pharmaceuticals
OLMA
$375M
| $10.3M | 1.27% | 3,743,875 | – | – |
|
|
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
| $9.96M | 1.22% | +950,000 | New | +$9.96M |
|
24
Altimmune
ALT
$338M
| $9.58M | 1.18% | +750,000 | New | +$9.58M |
|
|
BLU
25
DELISTED
BELLUS Health Inc.
BLU
| $8.45M | 1.04% | +800,000 | New | +$8.45M |
|